1. Home
  2. TPC vs BEAM Comparison

TPC vs BEAM Comparison

Compare TPC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tutor Perini Corporation

TPC

Tutor Perini Corporation

HOLD

Current Price

$81.93

Market Cap

3.1B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.61

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPC
BEAM
Founded
1894
2017
Country
United States
United States
Employees
N/A
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TPC
BEAM
Price
$81.93
$27.61
Analyst Decision
Strong Buy
Buy
Analyst Count
3
14
Target Price
$82.00
$46.00
AVG Volume (30 Days)
577.5K
2.1M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
0.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,103,323,000.00
$55,701,000.00
Revenue This Year
$25.77
N/A
Revenue Next Year
$14.81
$23.55
P/E Ratio
N/A
N/A
Revenue Growth
19.22
N/A
52 Week Low
$18.34
$13.53
52 Week High
$81.65
$36.44

Technical Indicators

Market Signals
Indicator
TPC
BEAM
Relative Strength Index (RSI) 73.59 43.79
Support Level $78.01 $27.00
Resistance Level $81.65 $32.26
Average True Range (ATR) 2.83 2.24
MACD 0.41 -0.68
Stochastic Oscillator 93.82 5.99

Price Performance

Historical Comparison
TPC
BEAM

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: